UCI statement on Fabio Taborre and UCI Professional Continental Team Androni Giocattoli-Sidermec

UCI Logo

The Union Cycliste Internationale (UCI) announces that it has notified Italian rider Fabio Taborre of an Adverse Analytical Finding (AAF) of FG-4592 (*) in a sample collected during an out-of-competition test on 16 June 2015.

The rider has the right to request and attend the analysis of the B sample.

In accordance with UCI Anti-doping Rules (UCI ADR), the rider has been provisionally suspended until the adjudication of the affair.

This constitutes the second AAF for a member of the UCI Professional Continental Team

Androni Giocattoli-Sidermec (**) since the beginning of 2015 and within a twelve-month period. Therefore article 7.12.1 UCI ADR providing for the suspension of the Team from 15 to 45 days (***) will be applied.

The UCI will refer the matter to the Disciplinary Commission which will render a decision in the upcoming days. At this stage of the procedure, the UCI will not comment any further on any of these matters.

(*) FG-4592 is a prohibited substance that has the property of stimulating the endogenous production of EPO.

(**) On 30 June 2015, the UCI Professional Continental Team Androni Giocattoli-Sidermec Italian rider Davide Appollonio was notified of an AAF of EPO in a sample collected during an out-of-competition test on 14 June 2015.

(***) Article 7.12.1 UCI ADR which entered into force on 1 January 2015.

Leave a comment

Please login to leave a comment.

Copyright © LawInSport Limited 2010 - 2020. These pages contain general information only. Nothing in these pages constitutes legal advice. You should consult a suitably qualified lawyer on any specific legal problem or matter. The information provided here was accurate as of the day it was posted; however, the law may have changed since that date. This information is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. LawInSport is not responsible for any actions taken or not taken on the basis of this information. Please refer to the full terms and conditions on our website.